Welcome to Markets Desk, here's what's moving the needle this Friday.
SoftBank's Masayoshi Son is making a massive bet on Europe, pledging seventy-five billion euros to build what would be the continent's largest artificial intelligence facility, planted squarely in France. The commitment puts Paris at the center of Son's global AI infrastructure push, signaling that sovereign AI capacity is becoming a serious geopolitical currency.
Shifting to energy markets, the Strait of Hormuz situation is drawing sharp attention from analysts and traders alike. Iran's blockade of the critical waterway has raised genuine questions about whether oil export flows through that corridor can ever fully recover to pre-conflict levels. With roughly a fifth of global seaborne crude passing through those waters, the structural implications for supply and pricing could be long-lasting, not temporary.
And in pharma, Pfizer is out with Phase three trial data showing its combination of TALZENNA and XTANDI cut disease progression risk by fifty-two percent in men with a specific form of metastatic prostate cancer. That is a clinically meaningful result in a hard-to-treat population, and it strengthens Pfizer's oncology pipeline at a moment when the company is under considerable pressure to demonstrate post-pandemic earnings durability.
That's the tape. Markets Desk, signing off the floor.
